Literature DB >> 8571316

Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.

A Greinacher1, S Alban, V Dummel, G Franz, C Mueller-Eckhardt.   

Abstract

HAT is the most frequent drug induced immune-thrombocytopenia. We recently identified multimolecular PF4/heparin complexes as the major antigen. In order to evaluate the structural requirements for formation of the antigenic complex, we chemically synthesized 13 glucan sulfates and used 5 heparin fractions (2.4-4.8 kD) and a synthesized pentasaccharide, representing the antithrombin III binding sequence of heparin, for further characterize the HAT antigen. In the presence of glucan sulfates and heparin, HAT antibodies caused platelet activation typically at low but not at high concentrations, as measured by 14C-5HT release. The concentration range giving the activation pattern depended on the degree of sulfation (DS) and molecular weight (MW) of the glucan sulfates but not on the type of glycosidic linkage of a polysaccharide. With linear glucan sulfates with a chain length of 35 monosaccharides, the critical DS to form the HAT antigen ranged between 0.60 and 1.20. Glycosidic branched glucan sulfates were able to form the HAT antigen at a lower DS and a lower MW than linear glucan sulfates. Platelet activation by HAT-antibodies in the presence of linear curdlan sulfate fractions was dependent on their MW. At a low concentration (0.01 microM) medium-size fractions (60 kD) caused platelet activation but neither small (12 kD) nor large fractions ( > 150 kD) did. At higher concentrations (2 microM) the opposite reaction pattern was observed. In the case of heparin, the optimal chain length for forming the HAT antigen is a hexadecasaccharide (4.8 kD). Antigen generation decreased with larger and smaller fractions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8571316

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  25 in total

Review 1.  Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

Authors:  N Lubenow; A Greinacher
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

2.  Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis.

Authors:  Yvette C Tanhehco; Ann H Rux; Bruce S Sachais
Journal:  Transfusion       Date:  2010-10-26       Impact factor: 3.157

3.  TecoflexTM functionalization by curdlan and its effect on protein adsorption and bacterial and tissue cell adhesion.

Authors:  Anand P Khandwekar; Deepak P Patil; Vaibhav Khandwekar; Yogesh S Shouche; Shilpa Sawant; Mukesh Doble
Journal:  J Mater Sci Mater Med       Date:  2008-12-18       Impact factor: 3.896

4.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

5.  Scientific considerations in the review and approval of generic enoxaparin in the United States.

Authors:  Sau Lee; Andre Raw; Lawrence Yu; Robert Lionberger; Naiqi Ya; Daniela Verthelyi; Amy Rosenberg; Steve Kozlowski; Keith Webber; Janet Woodcock
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

6.  Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies.

Authors:  Grace M Lee; Manali Joglekar; Maragatha Kuchibhatla; Sanjay Khandelwal; Rui Qi; Lubica Rauova; Gowthami M Arepally
Journal:  Blood Adv       Date:  2017-04-18

7.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

8.  Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery.

Authors:  Seiji Bito; Shigeki Miyata; Kiyoshi Migita; Mashio Nakamura; Kazuhito Shinohara; Tomotaro Sato; Takeharu Tonai; Motoyuki Shimizu; Yasuhiro Shibata; Kazuhiko Kishi; Chikara Kubota; Shinnosuke Nakahara; Toshihito Mori; Kazuo Ikeda; Shusuke Ota; Takeshi Minamizaki; Shigeru Yamada; Naofumi Shiota; Masataka Kamei; Satoru Motokawa
Journal:  Blood       Date:  2015-12-09       Impact factor: 22.113

9.  Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4.

Authors:  Miriam E Jaax; Krystin Krauel; Thomas Marschall; Sven Brandt; Julia Gansler; Birgitt Fürll; Bettina Appel; Silvia Fischer; Stephan Block; Christiane A Helm; Sabine Müller; Klaus T Preissner; Andreas Greinacher
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

Review 10.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.